Pear Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Pear Therapeutics's estimated annual revenue is currently $7.3M per year.
- Pear Therapeutics received $64.0M in venture funding in January 2019.
- Pear Therapeutics's estimated revenue per employee is $121,800
- Pear Therapeutics's total funding is $409M.
Employee Data
- Pear Therapeutics has 60 Employees.
- Pear Therapeutics grew their employee count by -81% last year.
Pear Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Health Economics and Real World Evidence | Reveal Email/Phone |
2 | VP Regulatory Affairs | Reveal Email/Phone |
3 | VP, Government Affairs | Reveal Email/Phone |
4 | Head Enterprise Solutions & Professional Services | Reveal Email/Phone |
5 | Director, State Government Affairs | Reveal Email/Phone |
6 | Regional Business Director | Reveal Email/Phone |
7 | Executive Assistant to Chief Medical Officer & Head Clinical Development | Reveal Email/Phone |
8 | Sr. Director, IT & Security | Reveal Email/Phone |
9 | Associate Director, Payroll & Equity Compensation | Reveal Email/Phone |
10 | Case Manager | Reveal Email/Phone |
Pear Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 88 | 13% | N/A | N/A |
#2 | $1.2M | 14 | -33% | N/A | N/A |
#3 | $5.3M | 50 | -26% | $29.3M | N/A |
#4 | $24.7M | 164 | -5% | $45.2M | N/A |
#5 | $4.8M | 43 | 5% | N/A | N/A |
#6 | $77M | 0 | N/A | $866M | N/A |
#7 | $0.3M | 4 | -33% | N/A | N/A |
#8 | $3.9M | 35 | 25% | N/A | N/A |
#9 | $234.6M | 1197 | 8% | N/A | N/A |
#10 | $18.6M | 133 | -16% | $23.3M | N/A |
What Is Pear Therapeutics?
At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product candidate, reSET-O for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.
keywords:Biotechnology,Gaming,Healthcare,Human Resources Hr,Information Security,Medical Diagnostics,Mobile,Pharmaceuticals,Security
$409M
Total Funding
60
Number of Employees
$7.3M
Revenue (est)
-81%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pear Therapeutics News
Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the...
Boston-based Pear's program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a...
In its first year-end financial report after going public via reverse merger last December, Pear Therapeutics inched past nearly all of its predictions for...
What You Should Know: – Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp (Nasdaq: THMA), a special purpose acquisition company (SPAC) whose management team is associated with the Pritzk ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.6M | 60 | -6% | N/A |
#2 | $7.8M | 60 | N/A | N/A |
#3 | $11.3M | 60 | -15% | N/A |
#4 | N/A | 60 | 9% | N/A |
#5 | $11.1M | 60 | 3% | N/A |
Pear Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-03-23 | $Undisclosed | Undisclosed | 5AM Ventures | Article |
| 2016-02-05 | $20.0M | Undisclosed | 5AM Ventures | Article |
| 2018-01-03 | $50.0M | B | Temasek | Article |
| 2019-01-07 | $64.0M | C | Temasek | Article |